It's worth noting that in lifestyle based weight loss, we do see a modest 16% decrease in obesity related cancer but not all cancer
however, there is no direct clinical evidence yet linking cagrilintide or retatrutide specifically to improvements in erectile function
CoA-LOT: BN20241018/CA
Once-Weekly Research Pattern Considerations Retatrutide's pharmacokinetics (~6-day half-life from fatty acid conjugation) support once-weekly research administration patterns
Consider: Escalating to next dose tier Evaluating adherence and lifestyle factors Checking for medication-interfering conditions (hypothyroidism, PCOS, sleep apnea) Discussing alternative treatments Dose-response comparison table: Wegovy vs Zepbound Data from STEP 1 (Wilding et al., NEJM 2021) and SURMOUNT-1 (Jastreboff et al., NEJM 2022)
Interestingly, there is further evidence indicating that mitochondrial dysfunction and oxidative stress contribute to epilepsy pathogenesis (Patel, 2004)